Amneal Pharmaceuticals

Amneal Pharmaceuticals has evolved from a pure generics manufacturer into a company focused on specialties and biosimilars. With the new Parkinson’s drug CREXONT, a growing biosimilar pipeline and expanded US manufacturing capacity, the company is addressing hospital supply shortages and strengthening its pricing power. This strategic realignment opens significant market opportunities for Amneal and is intended to sustainably improve margins. » More on finanzen.net

Amneal Pharmaceuticals’ stock rose to a 52-week high of $17.86 and is currently trading at $17.87, implying a market capitalization of $5.65 billion. Over the past year the share price gained 116.75%; InvestingPro rates the company’s financial health at 3.31 as “VERY GOOD” and considers the stock close to its fair value (P/E 46.56). Amneal beat expectations in Q1 2026 with EPS of $0.27 and revenue of $723 million. The company also received FDA approval for a romidepsin injection solution with 180 days of market exclusivity and reported positive interim results from the Phase 4 ELEVATE‑PD study for CREXONT. » More on de.investing.com

Amneal Pharmaceuticals shares rose to a 52-week high of $15.44; market capitalization is $4.87 billion and the stock is up 88% year-to-date. In Q1 2026 the company beat expectations with EPS of $0.27 (forecast $0.164) and revenue of $723 million. Amneal received FDA approval for a romidepsin injection solution with Competitive Generic Therapy status (180 days of market exclusivity) and reported positive interim results from the phase‑4 ELEVATE‑PD study of CREXONT, showing an increase in daily good-on time of about 3.03–3.33 hours. An InvestingPro analysis rates the stock near its fair value and assigns a financial health score of 3.4. » More on de.investing.com

Amneal plans to acquire Kashiv BioSciences for $750 million ($375m in cash, $375m in stock) plus up to $350 million in milestone payments to build a globally integrated biosimilar business. The transaction is expected to provide Amneal with immediate manufacturing capacity and approvals in the US, significantly expand R&D and manufacturing capabilities, and add more than 20 programs to the pipeline. Management expects $400–500 million in synergies, a combined revenue target of $4.25–4.5 billion by 2030, and a path to reduce net leverage below 3.0x by 2028; shareholders still must approve the acquisition. » More on de.investing.com

Amneal Pharmaceuticals reported adjusted EPS of $0.27 for Q1 2026 (forecast $0.164) and revenue of $723 million, slightly above expectations. The specialty segment grew 23% (including CREXONT) and adjusted EBITDA rose to $202 million; gross margin widened notably. The company raised its full-year guidance and expects the affordable medicines segment to grow 7–8% and a consolidated gross margin of around 45%. The stock showed premarket volatility, initially falling and then partially recovering. » More on de.investing.com